Serum TGF-β, serum MMP-1, and HOMA-IR as non-invasive predictors of fibrosis in Egyptian patients with NAFLD

Saudi Journal of Gastroenterology

Volumn 18, Issue 5, 2012, Pages 327-333

  Mahmoud, Adel A ^a   Bakir, Amal S ^a   Shabana, Sherif S ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

HOMA IR; Insulin resistance; Matrix metalloproteinase 1; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Noninvasive markers; Transforming growth factor beta 1

Indexed keywords

INSULIN; INTERSTITIAL COLLAGENASE; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DIET RESTRICTION; HISTOPATHOLOGY; HOMEOSTASIS; HOMEOSTASIS MODEL ASSESSMENT FOR INSULIN RESISTANCE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; PREDICTOR VARIABLE; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; BIOPSY; EGYPT; FATTY LIVER; FEMALE; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; LIVER; LIVER CIRRHOSIS; MALE; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84867314262     PISSN: 13193767     EISSN: 19984049     Source Type: Journal    
DOI: 10.4103/1319-3767.101132     Document Type: Article

References (28)

1. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: The diagnosis and staging of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2011;33:525-40.
2. Ratziu V, Charlotte F, Heurtier A. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898- 906.
3. Adams LA, Lymp JF, St Sauver J. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology 2005;129:113-21.
4. Adams LA, Sanderson S, Lindor KD. The histological course of nonalcoholic fatty liver disease: A longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005;42:132-8.
5. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-β as major players and therapeutic targets. J Cell Mol Med 2006;10:76-99.
6. Parkes J, Guha IN, Roderick P, Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol 2006;44:462-74.
7. Foucher J, Chanteloup E, Vergniol J, LeBail B, Adhoute X. Diagnosis of cirrhosis by transient elastography [fibroscan]: A prospective study. Gut 2006;55:403-8.
8. Hasegawa T, Yoneda M, Nakamura K. Plasma transforming growth factor-beta1 level and efficacy of alpha- tocopherol in patients with non- alcoholic steatohepatitis: A pilot study. Aliment Pharmacol Ther 2001;15:1667-72.
9. Ulrike WD, Stefan L. Non-invasive diagnosis and monitoring of liver fibrosis and cirrhosis. Best Pract Res Clin Gastroenterol 2009;23:453-60.
10. Guha IN, Parkes J, Roderick PR, Harris S, Rosenberg WM. Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut 2006;55:1650-60.
11. Kleiner DE, Brunt EM, van Natta M. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
12. Day CP, James OFW. Steatohepatitis. A tale of two hits. Gastroenterology 1998;114:842-5.
13. Guicciardi ME, Gores GJ. Apoptosis: A mechanism of acute and chronic liver injury. Gut 2005;54:1024-33.
14. Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-beta (TGF-β). Growth Factors 1993;8:1-9.
15. Soo HC, Hwan SB. Modulation of the transforming growth factorsignal transduction pathway by hepatitis C virus nonstructural 5A protein. J Biol Chem 2006;281:7468-78.
16. Cui W, Jin HB, Li ZW. Mechanism of the transforming growth factorbeta induction of fibronectin expression in hepatic stem-like cells. Braz J Med Biol Res 2010;43:36-42.
17. Kulasekaran P, Scavone CA, Rgers DS, Arenberg DA, Thannickal VJ, Horowitz JC. Endothelin-1 and transforming growth factor-beta independently induce fibroblast resistance to apoptosis via AKT activation. Am J Respir Cell Mol Biol 2009;41:484-93.
18. Zhang BB, Min Cai W, Weng HL, Hu ZR, Lu J, Zheng M, et al. Diagnostic value of platelet derived growth factor-BB, transforming growth factor-b1, matrix metalloproteinase-1 in serum and peripheral blood mononuclear cells for hepatic fibrosis. World J Gastroenterol 2003;9:2490-6.
19. Wahl S, Wen J, Moutsopoulos N. "TGF-β: A mobile purveyor of immune privilege". Immunol Rev 2006;213:213-27.
20. Kanzler S, Baumann M, Schimacher P, Dries V, Bayer E, Gerken G, et al. Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. J Viral Hepat 2001;8:430-7.
21. Murawaki Y, Ikuta Y, Idobe Y. Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis. J Gastroenterol Hepatol 1999;14:138-45.
22. Yin SS, Li XM, Wang TL, Jia JD, Qian LX. The relationship of serum metalloproteinase with the severity of liver fibrosis and inflammation. Zhonghua Gan Zang Bing Za Zhi 2004;12:666-8.
23. Abdel-Moneim SS, Mostafa EF, Osama A. Circulating matrix metalloproteinase-1 [MMP-1] and tissue inhibitor metalloproteinase-1 [TIMP-1] as serum markers of liver fibrosis in patients with chronic viral hepatitis. Arab J Gastroenterol 2008;9:39-43.
24. Paradis V, Perlemuter G, Bonvoust F. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: A potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001;34:738-44.
25. Ding X, Saxena NK, Lin S. The role of leptin and adiponectin: A novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am J Pathol 2005;166:1655-69.
26. Petta S, Camma C, DiMarco V. Insulin resistance is a major determinant of liver stiffness in non-diabetic patients with HCV genotype 1 chronic hepatitis. Aliment Pharmacol Ther 2009;30:603-13.
27. Sorrentino P, Terrecciano L, D'Angelo S, Ferbo U, Bracigliano A, Vecchione R. Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension. Am J Gastroenterol 2010;105:336-44.
28. Merchante N, Macias J, Ramayo E, Vergara S, Garcia-Garcia JA, Mira JA, et al. Insulin resistance is not associated with liver fibrosis progression in HIV/hepatitis C virus-co-infected patients. J Viral Hepat 2006;13:449-56.